{
    "clinical_study": {
        "@rank": "67296", 
        "arm_group": {
            "arm_group_label": "Carvedilol", 
            "arm_group_type": "Experimental", 
            "description": "Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day"
        }, 
        "brief_summary": {
            "textblock": "Estimate the effect of chronic beta-adrenergic receptor blockade with carvedilol on RV\n      function in patients with PAH.\n\n      Assess the safety and tolerability of chronic carvedilol therapy in patients with PAH"
        }, 
        "brief_title": "Carvedilol PAH A Pilot Study of Efficacy and Safety", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Hypertension", 
            "Cardiac MRI <40"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, open label, uncontrolled, pilot study examining the safety and\n      efficacy of beta-blocker therapy with carvedilol on RV function in stable PAH Patients with\n      World Health Organization (WHO) functional class II or III symptoms and RV ejection fraction\n      (EF) < 40%. Twenty-five evaluable patients will be enrolled at the University of Minnesota.\n\n      Specific Aims:\n\n      1.1 Primary Efficacy Endpoint: Adult males and females on a stable dose of an approved PAH\n      medication will undergo cardiac magnetic resonance imaging (MRI), right heart\n      catheterization (RHC), echocardiogram, 6-minute walk test (6-MWT), measurement of plasma\n      NT-ProBNP and serum catecholamine, and quality of life assessment. Patients will receive\n      carvedilol (3.25 mg/kg bid escalating to 25 mg/kg bid over 3 months). Testing is repeated at\n      the end of the study (month 6). RVEF measured by cardiac MRI is the primary efficacy\n      endpoint. We define a 5% increase in RVEF as a meaningful change."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects will be eligible to participate in the study if all of the following\n             conditions exist:\n\n          2. Age > 18 years\n\n          3. WHO category 1 pulmonary arterial hypertension (Dana Point 2008)\n\n          4. WHO functional class II-III\n\n          5. RVEF by cardiac MRI < 40%\n\n          6. Mean pulmonary artery pressure > 40 mm Hg\n\n          7. Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and\n             functional class in the past 3 months. Patient can be on either mono or combination\n             PAH-specific therapy\n\n        Exclusion Criteria:\n\n          -  1. Subjects will be excluded from participation in the study if any of the following\n             conditions exist: 2. Significant persistent bradycardia (resting heart rate < 60 bpm)\n             without a permanent pacemaker 3. Second or third degree AV block without a permanent\n             pacemaker 4. Significant sinus tachycardia (resting heart rate > 100 bpm) 5. Use of\n             anti-arrhythmic drugs 6. Hypotension defined as systolic blood pressure < 100 mmHg at\n             the time of enrollment 7. Significant illness in the past 30 days requiring\n             hospitalization 8. Acute decompensated right heart failure within past 30 days 9.\n             Known allergy or intolerance to carvedilol or other \u03b2 blockers 10. Cardiac index < 2\n             l/min/m2 or right atrial pressure > 15 mm Hg 11. Asthma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120339", 
            "org_study_id": "PAH"
        }, 
        "intervention": {
            "arm_group_label": "Carvedilol", 
            "intervention_name": "Carvedilol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Carvedilol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hypertension", 
            "PAH"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55414"
                }, 
                "name": "University of Minnesota"
            }, 
            "investigator": [
                {
                    "last_name": "Thenappan Thenappan, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Marc Pritzker, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Monica Colvin-Adams, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kenneth Weir, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety", 
        "overall_contact": {
            "email": "nels8514@umn.edu", 
            "last_name": "Jennifer Nelson, RN", 
            "phone": "612-625-0455"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Thenappan Thenappan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1.\tThe primary efficacy outcome is the mean change in RVEF as measured by cardiac MRI before and after 6 months of carvedilol treatment. An improvement of 5% will be considered to be clinically significant. Assessment of the RV is challenging due to its complex geometry.  Cardiac MRI offers the ability to acquire 3-dimensional datasets that do not require geometric modeling. In addition to being highly reproducible40, RVEF measured by cardiac MRI can be used to identify PAH patients that are likely to have clinical worsening41.  The prognostic ability of cardiac MRI-measurements of RVEF is similar to that as mean pulmonary artery pressure and exercise capacity", 
            "measure": "Mean change in RVEF", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The primary safety outcome is the absence of adverse events associated with carvedilol including hypotension (<90 mm Hg), bradycardia (<50 bpm or advanced atrioventricular nodal block), bronchospam, or acute decompensated right heart failure requiring hospitalization.", 
            "measure": "Absence of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}